SIBO Breath Test: What Your Number Changes About Your Treatment

What the SIBO Breath Test Actually Measures

The test captures gases that human cells cannot produce. When bacteria in the small intestine ferment a sugar substrate (lactulose or glucose), they release hydrogen and methane. Those gases diffuse into the bloodstream, travel to the lungs, and exit in exhaled breath, where a handheld or lab-grade device records them in parts per million (ppm) at timed intervals over 90 to 180 minutes [1].

Hydrogen comes from a broad range of gram-negative organisms. Methane comes almost exclusively from archaea, most commonly Methanobrevibacter smithii, which technically makes methane-positive results an "intestinal methanogen overgrowth" (IMO) rather than classical SIBO [2]. This distinction matters because archaea are not bacteria and do not respond to the same antibiotics. A 2017 consensus from the North American Consensus group, published in the American Journal of Gastroenterology, standardized the diagnostic cutoffs that clinicians now use worldwide [3]. Your report will list values at each collection point, usually every 15 or 20 minutes, and the pattern of rise tells your provider which gas is dominant and how aggressive treatment needs to be.

The Cutoffs That Define a Positive Result

A hydrogen rise of 20 ppm or more above baseline within the first 90 minutes of testing is the current North American Consensus threshold for hydrogen-positive SIBO [3]. For methane, a level of 10 ppm or higher at any single time point during the test, including the baseline reading, qualifies as methane-positive [3].

These numbers replaced older, less standardized criteria. Before the 2017 consensus, some labs used a 12-ppm hydrogen cutoff and others used 20 ppm, creating diagnostic inconsistency. Dr. Mark Pimentel, a gastroenterologist at Cedars-Sinai and lead author of the consensus paper, stated: "We needed a single set of criteria so that a positive test in Los Angeles meant the same thing as a positive test in Boston" [3]. The 20-ppm hydrogen threshold was selected because it offered the best sensitivity-specificity balance in validation studies.

A "flat-line" result, where neither hydrogen nor methane rises at all, may indicate a hydrogen sulfide-dominant overgrowth. Newer trio-gas devices like the AIRE 2 or the trio-SMART device can detect hydrogen sulfide, though the clinical cutoff for this third gas (≥3 ppm) is still considered investigational [4].

Hydrogen-Positive SIBO: The Rifaximin Protocol

If your breath test shows a hydrogen rise of ≥20 ppm with methane staying below 10 ppm, you have hydrogen-dominant SIBO. The standard treatment is rifaximin (Xifaxan) 550 mg taken three times daily for 14 days [5].

Rifaximin works because it stays almost entirely inside the gut lumen. Systemic absorption is less than 0.4%, which limits side effects [5]. In the TARGET 1 and TARGET 2 trials (combined N=1,260), rifaximin produced adequate relief of global IBS symptoms in 40.8% of patients versus 31.2% for placebo, with a number needed to treat (NNT) of 10.2 [6]. When looking specifically at breath test normalization, pooled data show that rifaximin clears hydrogen-positive SIBO in roughly 64% of cases after a single 14-day course [7].

Some clinicians extend to 21 days or repeat the 14-day course if the post-treatment breath test still shows elevation. There is no large randomized trial comparing 14-day versus 21-day regimens head-to-head, but retrospective series suggest that a second course captures an additional 15% to 20% of non-responders [7].

Methane-Positive Results: Why One Antibiotic Is Not Enough

Methane on the breath test changes the treatment approach significantly. Rifaximin alone performs poorly against methanogens. A retrospective analysis by Pimentel and colleagues found that rifaximin monotherapy normalized methane in only about 28% of patients [8]. Adding neomycin 500 mg twice daily for 14 days alongside rifaximin raised that normalization rate to 87% [8]. The combination is now considered standard of care for methane-positive results.

Methane itself is not just a marker of overgrowth. It directly slows gut transit. A study published in Neurogastroenterology & Motility showed that methane infused into the small intestine reduced transit time by 59% in a canine model, which explains the strong clinical association between methane on breath testing and constipation-predominant symptoms [9]. This is why patients with high methane values and constipation often see both their gas levels and their bowel patterns improve once the methane drops.

Dr. Ali Rezaie, co-director of the GI Motility Program at Cedars-Sinai, has noted: "Methane is not just a bystander gas. It has direct pharmacologic effects on gut motility, and until you bring that number down, the constipation will persist" [10].

An alternative for patients who cannot tolerate neomycin (which carries a small risk of ototoxicity and nephrotoxicity with prolonged use) is lovastatin, a statin that inhibits a key enzyme in archaeal cell membranes. Early-phase data are promising but this use remains off-label and investigational [11].

Mixed Gas Patterns and What They Mean for Your Prescription

Some patients produce both hydrogen and methane above their respective thresholds. This mixed pattern occurs in roughly 20% to 35% of positive breath tests [12]. Treatment for a mixed result follows the methane-positive protocol (rifaximin plus neomycin for 14 days) because single-agent rifaximin will likely leave the methane component untreated.

The total area under the curve for gas production, not just the peak value, gives your clinician a sense of bacterial load. A hydrogen peak of 85 ppm tells a different story than a peak of 25 ppm. Higher gas production often correlates with more severe symptoms and may predict a longer course of treatment or the need for a repeat cycle [13]. Your provider should compare both the peak and the overall pattern against your symptom severity when deciding duration and whether to add adjunctive therapy like a biofilm disruptor or a partially hydrolyzed guar gum (PHGG) prebiotic.

Substrate Choice: Lactulose vs. Glucose and Why It Matters

The sugar solution you drink before the test affects what the result can detect. Glucose is absorbed in the proximal small intestine, so a glucose breath test primarily detects overgrowth in the upper small bowel. Lactulose is not absorbed and travels the full length of the small intestine, making it more sensitive to distal overgrowth [14].

A meta-analysis of 14 studies (N=1,432) published in the Journal of Clinical Gastroenterology found that the glucose breath test had a pooled sensitivity of 54.5% and specificity of 83.2%, while lactulose had a sensitivity of 42.0% but a specificity of 70.6% [14]. Neither test is perfect. False positives with lactulose can occur when the substrate reaches the colon prematurely in patients with rapid transit, producing a gas rise that mimics SIBO. Your clinician may choose glucose if proximal overgrowth is suspected (post-surgical anatomy, for example) and lactulose for a broader survey.

This distinction has direct treatment implications. A glucose-positive result localizes the problem and may respond to a single standard-length antibiotic course. A lactulose-positive result with a late rise (after 90 minutes) may actually represent colonic fermentation rather than true SIBO, and your provider might recommend retesting with glucose before starting antibiotics.

What Happens After Treatment: The Retest and Recurrence Problem

A follow-up breath test 2 to 4 weeks after completing antibiotics confirms whether treatment worked. Normalization means hydrogen stays below the 20-ppm rise threshold and methane stays below 10 ppm throughout the collection period. If values drop but do not fully normalize, a second treatment course is typically offered before moving to alternative strategies [15].

Recurrence is common. A prospective study in Digestive Diseases and Sciences found that SIBO recurred in 12.6% of patients at 3 months and 43.7% at 9 months without prokinetic therapy [16]. Adding a prokinetic agent, most commonly low-dose erythromycin (50 mg at bedtime) or prucalopride (1 to 2 mg daily), reduced recurrence by approximately half in observational data [16]. The prokinetic works by stimulating the migrating motor complex (MMC), the "housekeeper wave" that sweeps bacteria out of the small intestine between meals.

Diet also affects recurrence. A low-fermentation eating pattern during and immediately after treatment can reduce symptom flares, but long-term restriction of fermentable carbohydrates (as in a strict low-FODMAP diet) may starve beneficial colonic bacteria. The current expert recommendation is to use dietary restriction as a short-term bridge (4 to 6 weeks) while the prokinetic re-establishes normal motility, then gradually reintroduce fermentable foods [17].

Borderline Results: The Gray Zone Between 15 and 20 ppm

Not every result is a clear positive or negative. A hydrogen rise of 15 to 19 ppm falls below the consensus cutoff but above what most healthy controls produce. No guideline formally addresses this range. Some clinicians treat empirically if symptoms are consistent. Others retest after optimizing preparation (ensuring the patient completed the full 24-hour prep diet, which eliminates high-fiber and high-sugar foods that can inflate baseline readings).

A 2020 study in Alimentary Pharmacology & Therapeutics found that patients with "borderline" hydrogen results (15 to 19 ppm rise) who received rifaximin had symptom improvement rates only marginally better than placebo (38% vs. 32%), suggesting that the 20-ppm cutoff has reasonable clinical meaning [18]. If you fall in this range, a repeat test or a trial of a prokinetic without antibiotics may be a more measured first step.

How Medications and Conditions Alter Your Result

Proton pump inhibitors (PPIs) increase the risk of SIBO by reducing the gastric acid barrier that normally limits bacterial colonization of the upper gut. A meta-analysis of 11 studies (N=3,134) published in the Journal of Gastroenterology found that PPI use was associated with a 2.28-fold increased odds of a positive SIBO breath test (95% CI: 1.24 to 4.21) [19]. If you are on a PPI and test positive, your provider may discuss whether the PPI can be stepped down or switched to an H2 receptor antagonist after SIBO treatment.

Opioids slow intestinal motility and independently raise SIBO risk. Diabetes with autonomic neuropathy impairs the MMC. Prior abdominal surgery, especially ileocecal valve resection, removes the anatomical barrier between the colon and small intestine. Hypothyroidism slows gut transit. Each of these underlying conditions must be addressed alongside antibiotic treatment, or the breath test will simply turn positive again within months [20].

Antibiotics taken for unrelated infections within the 4 weeks before testing can produce false-negative results by temporarily suppressing bacterial populations. The North American Consensus recommends waiting at least 4 weeks after any systemic antibiotic course before performing a SIBO breath test [3].

Tracking Your Numbers Over Time

Serial breath testing after each treatment round gives your clinician a trend line. A patient whose peak hydrogen drops from 80 ppm to 35 ppm after the first course is responding but not yet clear, and a second course is warranted. A patient whose methane drops from 45 ppm to 8 ppm is now below threshold, and the focus shifts to recurrence prevention with prokinetics and dietary management.

Gas values do not need to reach zero. A methane reading of 5 ppm or a hydrogen rise of 10 ppm is within the normal range that healthy individuals produce. The goal is to get below the diagnostic threshold and keep you there. Clinicians at the Cedars-Sinai MAST (Medically Associated Science and Technology) program have published case series showing that patients who achieve and maintain sub-threshold gas levels for 6 months have a less than 15% recurrence rate over the subsequent year, compared to 44% for those who stop treatment the moment symptoms improve [16].

Your post-treatment breath test result also informs the choice of long-term prokinetic. Patients with residual methane elevation (even below 10 ppm) may benefit from ongoing low-dose rifaximin cycling (2 weeks on, 2 weeks off) in addition to a prokinetic, though this approach lacks large randomized trial support and should be discussed with your gastroenterologist on an individual basis.